Back to Search Start Over

Acellbia® and Mabtera® are recognize CD20-positive cells with equal efficiency

Authors :
V. A. Misyurin
A. V. Misyurin
A. E. Misyurina
Yu. P. Finashutina
M. A. Baryshnikovа
O. S. Burova
S. K. Kravchenko
Source :
Онкогематология, Vol 10, Iss 4, Pp 56-59 (2015)
Publication Year :
2015
Publisher :
ABV-press, 2015.

Abstract

In present study were compared characteristics of rituximab produced by Hoffmann–La Roche (Mabtera®) and first domestic biosimilar Acellbia® from Biocad Company. Concentration of protein was measured using Bradford, s method. According to our results, protein concentration in formulations was the same. We electrophoresed formulations in denaturing conditions. Protein from formulations was denatured into fragments. Heavy and light chains of immunoglobulin were observed in gel. Finally, we performed flow cytometry where rituximab was used as primary antibody to detect CD20-positive B-cells of patients with B-cell chronic lymphocytic leukemia. Both Mabtera® and Acellbia® recognized the same number of cells. Thus, assays performed in vitro submitted identity of Mabtera® and Acellbia® characteristics.

Details

Language :
Russian
ISSN :
18188346 and 24134023
Volume :
10
Issue :
4
Database :
Directory of Open Access Journals
Journal :
Онкогематология
Publication Type :
Academic Journal
Accession number :
edsdoj.956f6b6bcae84a1494e866ac0b514d24
Document Type :
article
Full Text :
https://doi.org/10.17650/1818-8346-2015-10-4-56-59